[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3XOzbZPeYKnU2MLQ5hHKjDpoDfAwOZrW9kCGkD9Intg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"St George's, University of London",[4],106,false,8,9,58854,0,69,[14,17,20,23,25,27,29,32],{"name":15,"count":16},"Stroke",7,{"name":18,"count":19},"Hypertension",6,{"name":21,"count":22},"Group B Strep Infection",4,{"name":24,"count":22},"HIV Infections",{"name":26,"count":22},"Pertussis",{"name":28,"count":22},"Pregnancy Related",{"name":30,"count":31},"Group B Streptococcus Carrier in Childbirth",3,{"name":33,"count":31},"Group B Streptococcal Infection, Late-Onset",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,72,101,127,153,179,205,223,251,269,298,323,352,370,388,406,433,451,480,508,533,559,585,611,638,663,681,705,729,756,774,792,819,837,861,888,906,924,958,984,1009,1027,1045,1069,1095,1118,1136,1161,1187,1213,1231,1253],{"intervention":44,"totalTrials":45,"cells":46},"Prostin E2 Vaginal Suppository",1,{"EARLY_PHASE1":47,"PHASE1":49,"PHASE2":51,"PHASE3":53,"PHASE4":55,"NA":70},{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[],{"trials":56,"activeCount":11},[57],{"nctId":58,"briefTitle":59,"status":60,"phases":61,"primaryCompletion":62,"completion":63,"start":64,"enrollment":65,"conditions":66,"interventions":69},"NCT03199820","Balloon Catheter Versus Propess for Labour Induction","UNKNOWN",[40],"2019-01-31","2019-05-31","2017-09-22",120,[67,68],"Childbirth Problems","Labor Complication",[44],{"trials":71,"activeCount":11},[],{"intervention":73,"totalTrials":45,"cells":74},"4CMenB Vaccine",{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":99},{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[85],{"nctId":86,"briefTitle":87,"status":88,"phases":89,"primaryCompletion":90,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":98},"NCT03125616","Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B","COMPLETED",[40],"2019-09-02","2020-08-28","2017-08-01",136,[95,96,97],"Prematurity","Vaccination","Meningococcal Disease",[73,73,73,73],{"trials":100,"activeCount":11},[],{"intervention":102,"totalTrials":45,"cells":103},"Pregabalin or Duloxetine or Placebo",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":125},{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[],{"trials":111,"activeCount":11},[],{"trials":113,"activeCount":11},[114],{"nctId":115,"briefTitle":116,"status":88,"phases":117,"primaryCompletion":118,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT02612233","Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin",[40],"2016-05","2016-07","2013-09",81,[123],"Hand Osteoarthritis",[102],{"trials":126,"activeCount":11},[],{"intervention":128,"totalTrials":45,"cells":129},"Pertussis containing vaccine",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":151},{"trials":131,"activeCount":11},[],{"trials":133,"activeCount":11},[],{"trials":135,"activeCount":11},[],{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[140],{"nctId":141,"briefTitle":142,"status":60,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":150},"NCT03908164","Optimising the Timing of Whooping Cough Immunisation in MUMs",[40],"2020-12-10","2021-05","2019-05-07",354,[28,149,26],"Immunization; Infection",[128],{"trials":152,"activeCount":11},[],{"intervention":154,"totalTrials":45,"cells":155},"Metformin",{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":164,"NA":177},{"trials":157,"activeCount":11},[],{"trials":159,"activeCount":11},[],{"trials":161,"activeCount":11},[],{"trials":163,"activeCount":11},[],{"trials":165,"activeCount":11},[166],{"nctId":167,"briefTitle":168,"status":88,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":176},"NCT01247870","Metformin in Chronic Obstructive Pulmonary Disease",[40],"2014-03","2014-05","2011-01",52,[175],"Chronic Obstructive Pulmonary Disease",[154],{"trials":178,"activeCount":11},[],{"intervention":180,"totalTrials":45,"cells":181},"Abatacept",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":203},{"trials":183,"activeCount":11},[],{"trials":185,"activeCount":11},[],{"trials":187,"activeCount":11},[],{"trials":189,"activeCount":11},[],{"trials":191,"activeCount":11},[192],{"nctId":193,"briefTitle":194,"status":88,"phases":195,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":199,"interventions":201},"NCT04255134","Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)",[40],"2022-10-26","2020-09-07",18,[200],"Rheumatoid Arthritis",[180,202],"Adalimumab",{"trials":204,"activeCount":11},[],{"intervention":202,"totalTrials":45,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":221},{"trials":208,"activeCount":11},[],{"trials":210,"activeCount":11},[],{"trials":212,"activeCount":11},[],{"trials":214,"activeCount":11},[],{"trials":216,"activeCount":11},[217],{"nctId":193,"briefTitle":194,"status":88,"phases":218,"primaryCompletion":196,"completion":196,"start":197,"enrollment":198,"conditions":219,"interventions":220},[40],[200],[180,202],{"trials":222,"activeCount":11},[],{"intervention":224,"totalTrials":45,"cells":225},"Bexsero®",{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":249},{"trials":227,"activeCount":11},[],{"trials":229,"activeCount":11},[],{"trials":231,"activeCount":11},[],{"trials":233,"activeCount":11},[],{"trials":235,"activeCount":11},[236],{"nctId":237,"briefTitle":238,"status":60,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":247},"NCT03682939","Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population",[40],"2020-06","2021-03","2019-02-21",55,[245,246,24],"Hiv","Meningitis, Meningococcal",[224,248],"Menveo®",{"trials":250,"activeCount":11},[],{"intervention":248,"totalTrials":45,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":267},{"trials":254,"activeCount":11},[],{"trials":256,"activeCount":11},[],{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[263],{"nctId":237,"briefTitle":238,"status":60,"phases":264,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":265,"interventions":266},[40],[245,246,24],[224,248],{"trials":268,"activeCount":11},[],{"intervention":270,"totalTrials":45,"cells":271},"Lokelma Oral Product",{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":294,"NA":296},{"trials":273,"activeCount":11},[],{"trials":275,"activeCount":11},[],{"trials":277,"activeCount":11},[],{"trials":279,"activeCount":11},[280],{"nctId":281,"briefTitle":282,"status":88,"phases":283,"primaryCompletion":284,"completion":284,"start":285,"enrollment":286,"conditions":287,"interventions":293},"NCT05004363","Lokelma for RAAS Maximisation in CKD & Heart Failure.",[39],"2024-07-01","2022-01-19",112,[288,289,290,291,292],"Chronic Kidney Diseases","Heart Failure With Reduced Ejection Fraction","Hyperkalemia","ACE Inhibitor Induced Hyperkalaemia","Mineralocorticoid Resistant Hyperkalemia",[270],{"trials":295,"activeCount":11},[],{"trials":297,"activeCount":11},[],{"intervention":299,"totalTrials":45,"cells":300},"Cholecalciferol",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":319,"NA":321},{"trials":302,"activeCount":11},[],{"trials":304,"activeCount":11},[],{"trials":306,"activeCount":11},[],{"trials":308,"activeCount":11},[309],{"nctId":310,"briefTitle":311,"status":88,"phases":312,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":318},"NCT02005718","Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD",[39],"2013-06","2010-06",36,[317],"CKd Patients With Stage 3 and 4",[299],{"trials":320,"activeCount":11},[],{"trials":322,"activeCount":11},[],{"intervention":324,"totalTrials":45,"cells":325},"Rifampicin",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":348,"NA":350},{"trials":327,"activeCount":11},[],{"trials":329,"activeCount":11},[],{"trials":331,"activeCount":11},[],{"trials":333,"activeCount":11},[334],{"nctId":335,"briefTitle":336,"status":88,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT02581527","A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis",[39],"2022-01-01","2022-07-31","2017-02-01",672,[343],"Pulmonary Tuberculosis",[324,345,346,347],"Isoniazid","Ethambutol","Pyrazinamide",{"trials":349,"activeCount":11},[],{"trials":351,"activeCount":11},[],{"intervention":345,"totalTrials":45,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":366,"NA":368},{"trials":355,"activeCount":11},[],{"trials":357,"activeCount":11},[],{"trials":359,"activeCount":11},[],{"trials":361,"activeCount":11},[362],{"nctId":335,"briefTitle":336,"status":88,"phases":363,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":364,"interventions":365},[39],[343],[324,345,346,347],{"trials":367,"activeCount":11},[],{"trials":369,"activeCount":11},[],{"intervention":346,"totalTrials":45,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":384,"NA":386},{"trials":373,"activeCount":11},[],{"trials":375,"activeCount":11},[],{"trials":377,"activeCount":11},[],{"trials":379,"activeCount":11},[380],{"nctId":335,"briefTitle":336,"status":88,"phases":381,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":382,"interventions":383},[39],[343],[324,345,346,347],{"trials":385,"activeCount":11},[],{"trials":387,"activeCount":11},[],{"intervention":347,"totalTrials":45,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":402,"NA":404},{"trials":391,"activeCount":11},[],{"trials":393,"activeCount":11},[],{"trials":395,"activeCount":11},[],{"trials":397,"activeCount":11},[398],{"nctId":335,"briefTitle":336,"status":88,"phases":399,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":400,"interventions":401},[39],[343],[324,345,346,347],{"trials":403,"activeCount":11},[],{"trials":405,"activeCount":11},[],{"intervention":407,"totalTrials":45,"cells":408},"Antiplatelet",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":429,"NA":431},{"trials":410,"activeCount":11},[],{"trials":412,"activeCount":11},[],{"trials":414,"activeCount":11},[],{"trials":416,"activeCount":11},[417],{"nctId":418,"briefTitle":419,"status":88,"phases":420,"completion":171,"start":421,"enrollment":422,"conditions":423,"interventions":427},"NCT00238667","To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection",[39],"2005-11",250,[424,425,426,15],"Cervical Artery Dissection","Carotid Artery Dissection","Vertebral Artery Dissection",[407,428],"Anticoagulant",{"trials":430,"activeCount":11},[],{"trials":432,"activeCount":11},[],{"intervention":428,"totalTrials":45,"cells":434},{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":447,"NA":449},{"trials":436,"activeCount":11},[],{"trials":438,"activeCount":11},[],{"trials":440,"activeCount":11},[],{"trials":442,"activeCount":11},[443],{"nctId":418,"briefTitle":419,"status":88,"phases":444,"completion":171,"start":421,"enrollment":422,"conditions":445,"interventions":446},[39],[424,425,426,15],[407,428],{"trials":448,"activeCount":11},[],{"trials":450,"activeCount":11},[],{"intervention":452,"totalTrials":45,"cells":453},"Donepezil",{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":474,"PHASE4":476,"NA":478},{"trials":455,"activeCount":11},[],{"trials":457,"activeCount":11},[],{"trials":459,"activeCount":11},[460],{"nctId":461,"briefTitle":462,"status":463,"phases":464,"primaryCompletion":465,"completion":465,"start":466,"enrollment":467,"conditions":468,"interventions":473},"NCT02222727","Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage","TERMINATED",[38],"2016-11","2014-01",19,[469,470,471,472],"Aneurysmal Subarachnoid Hemorrhage","Delayed Neurological Deficit","Delayed Cerebral Ischemia","Vasospasm",[452],{"trials":475,"activeCount":11},[],{"trials":477,"activeCount":11},[],{"trials":479,"activeCount":11},[],{"intervention":481,"totalTrials":45,"cells":482},"EE-TP",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":502,"PHASE4":504,"NA":506},{"trials":484,"activeCount":11},[],{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[489],{"nctId":490,"briefTitle":491,"status":492,"phases":493,"primaryCompletion":494,"completion":495,"start":496,"enrollment":11,"conditions":497,"interventions":501},"NCT03866954","Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy","WITHDRAWN",[38],"2027-09","2027-12","2024-11",[498,499,500],"Mitochondrial Diseases","Metabolic Disease","Inborn Errors of Metabolism",[481],{"trials":503,"activeCount":11},[],{"trials":505,"activeCount":11},[],{"trials":507,"activeCount":11},[],{"intervention":509,"totalTrials":45,"cells":510},"GBS6",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":512,"activeCount":11},[],{"trials":514,"activeCount":11},[],{"trials":516,"activeCount":11},[517],{"nctId":518,"briefTitle":519,"status":60,"phases":520,"primaryCompletion":521,"completion":521,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT05832502","Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE)",[38],"2025-09-30","2022-10-14",300,[525],"Group B Streptococcal Infection",[509],{"trials":528,"activeCount":11},[],{"trials":530,"activeCount":11},[],{"trials":532,"activeCount":11},[],{"intervention":534,"totalTrials":45,"cells":535},"Insulin",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":553,"PHASE4":555,"NA":557},{"trials":537,"activeCount":11},[],{"trials":539,"activeCount":11},[],{"trials":541,"activeCount":11},[542],{"nctId":543,"briefTitle":544,"status":88,"phases":545,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":552},"NCT00764556","Phase II Study of Safety and Feasibility of Intensive Blood Glucose Control With Insulin on Acute Medical Wards",[38],"2009-05","2008-05",20,[550,551],"COPD","Hyperglycemia",[534],{"trials":554,"activeCount":11},[],{"trials":556,"activeCount":11},[],{"trials":558,"activeCount":11},[],{"intervention":560,"totalTrials":45,"cells":561},"Aspirin",{"EARLY_PHASE1":562,"PHASE1":564,"PHASE2":566,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":563,"activeCount":11},[],{"trials":565,"activeCount":11},[],{"trials":567,"activeCount":11},[568],{"nctId":569,"briefTitle":570,"status":463,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":578},"NCT02333123","Aspirin for Venous Ulcers: Randomised Trial (AVURT)",[38],"2016-08-18","2016-11-11","2015-07-10",26,[577],"Venous Leg Ulcer",[560],{"trials":580,"activeCount":11},[],{"trials":582,"activeCount":11},[],{"trials":584,"activeCount":11},[],{"intervention":586,"totalTrials":45,"cells":587},"Ajmaline",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":605,"PHASE4":607,"NA":609},{"trials":589,"activeCount":11},[],{"trials":591,"activeCount":11},[],{"trials":593,"activeCount":11},[594],{"nctId":595,"briefTitle":596,"status":60,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":600,"conditions":601,"interventions":604},"NCT02933437","The Response To Ajmaline Provocation in Healthy Subjects",[38],"2019-12","2017-10-22",100,[602,603],"Brugada Syndrome","Sudden Death",[586],{"trials":606,"activeCount":11},[],{"trials":608,"activeCount":11},[],{"trials":610,"activeCount":11},[],{"intervention":612,"totalTrials":45,"cells":613},"Artesunate 200mg",{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":632,"PHASE4":634,"NA":636},{"trials":615,"activeCount":11},[],{"trials":617,"activeCount":11},[],{"trials":619,"activeCount":11},[620],{"nctId":621,"briefTitle":622,"status":60,"phases":623,"primaryCompletion":624,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":631},"NCT02633098","A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II\u002FIII Colorectal Cancer",[38],"2022-12-31","2025-10-31","2017-04-26",200,[629,630],"Colorectal Cancer","Bowel Cancer",[612],{"trials":633,"activeCount":11},[],{"trials":635,"activeCount":11},[],{"trials":637,"activeCount":11},[],{"intervention":639,"totalTrials":45,"cells":640},"Standard of care vaccines",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":645,"PHASE3":657,"PHASE4":659,"NA":661},{"trials":642,"activeCount":11},[],{"trials":644,"activeCount":11},[],{"trials":646,"activeCount":11},[647],{"nctId":648,"briefTitle":649,"status":88,"phases":650,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":655},"NCT04589312","Maternal Pertussis Wholecell Responses",[38],"2023-06-30","2020-10-21",181,[26],[639,656],"Boostagen,",{"trials":658,"activeCount":11},[],{"trials":660,"activeCount":11},[],{"trials":662,"activeCount":11},[],{"intervention":656,"totalTrials":45,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":677,"NA":679},{"trials":666,"activeCount":11},[],{"trials":668,"activeCount":11},[],{"trials":670,"activeCount":11},[671],{"nctId":648,"briefTitle":649,"status":88,"phases":672,"primaryCompletion":651,"completion":651,"start":652,"enrollment":653,"conditions":673,"interventions":674},[38],[26],[639,656],{"trials":676,"activeCount":11},[],{"trials":678,"activeCount":11},[],{"trials":680,"activeCount":11},[],{"intervention":682,"totalTrials":45,"cells":683},"Tadalafil",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":685,"activeCount":11},[],{"trials":687,"activeCount":11},[],{"trials":689,"activeCount":11},[690],{"nctId":691,"briefTitle":692,"status":88,"phases":693,"primaryCompletion":694,"completion":694,"start":695,"enrollment":243,"conditions":696,"interventions":698},"NCT02450253","Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial",[38],"2018-01-25","2015-09",[697],"Dementia, Vascular",[682],{"trials":700,"activeCount":11},[],{"trials":702,"activeCount":11},[],{"trials":704,"activeCount":11},[],{"intervention":706,"totalTrials":45,"cells":707},"CN54gp140 glycoprotein-hsp70 conjugate vaccine",{"EARLY_PHASE1":708,"PHASE1":710,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":709,"activeCount":11},[],{"trials":711,"activeCount":11},[712],{"nctId":713,"briefTitle":714,"status":88,"phases":715,"primaryCompletion":716,"completion":717,"start":718,"enrollment":8,"conditions":719,"interventions":720},"NCT01285141","Reactogenicity and Immunogenicity of Cervico-vaginal CN54gp140-hsp70 Conjugate Vaccine",[37],"2012-01","2012-12","2011-07",[24],[706],{"trials":722,"activeCount":11},[],{"trials":724,"activeCount":11},[],{"trials":726,"activeCount":11},[],{"trials":728,"activeCount":11},[],{"intervention":730,"totalTrials":45,"cells":731},"Human Immunodeficiency Virus glycoprotein 140",{"EARLY_PHASE1":732,"PHASE1":734,"PHASE2":748,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":733,"activeCount":11},[],{"trials":735,"activeCount":11},[736],{"nctId":737,"briefTitle":738,"status":463,"phases":739,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT00369031","Safety Study Of Nasal HIV Vaccine Adjuvanted With LTK63",[37],"2007-11","2008-03","2006-09",31,[24],[730,746,747],"HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant","Labile Toxin mutant LTK63 adjuvant",{"trials":749,"activeCount":11},[],{"trials":751,"activeCount":11},[],{"trials":753,"activeCount":11},[],{"trials":755,"activeCount":11},[],{"intervention":746,"totalTrials":45,"cells":757},{"EARLY_PHASE1":758,"PHASE1":760,"PHASE2":766,"PHASE3":768,"PHASE4":770,"NA":772},{"trials":759,"activeCount":11},[],{"trials":761,"activeCount":11},[762],{"nctId":737,"briefTitle":738,"status":463,"phases":763,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":764,"interventions":765},[37],[24],[730,746,747],{"trials":767,"activeCount":11},[],{"trials":769,"activeCount":11},[],{"trials":771,"activeCount":11},[],{"trials":773,"activeCount":11},[],{"intervention":747,"totalTrials":45,"cells":775},{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":790},{"trials":777,"activeCount":11},[],{"trials":779,"activeCount":11},[780],{"nctId":737,"briefTitle":738,"status":463,"phases":781,"primaryCompletion":740,"completion":741,"start":742,"enrollment":743,"conditions":782,"interventions":783},[37],[24],[730,746,747],{"trials":785,"activeCount":11},[],{"trials":787,"activeCount":11},[],{"trials":789,"activeCount":11},[],{"trials":791,"activeCount":11},[],{"intervention":793,"totalTrials":45,"cells":794},"HIV glycoprotein CN54gp140",{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":811,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":796,"activeCount":11},[],{"trials":798,"activeCount":11},[799],{"nctId":800,"briefTitle":801,"status":463,"phases":802,"primaryCompletion":803,"completion":804,"start":805,"enrollment":806,"conditions":807,"interventions":809},"NCT00637962","Reactogenicity and Immunogenicity of Vaginal CNgp140",[37],"2008-10","2009-01","2007-09",23,[24,808],"Acquired Immune Deficiency Syndrome",[793,810],"Carbopol 974",{"trials":812,"activeCount":11},[],{"trials":814,"activeCount":11},[],{"trials":816,"activeCount":11},[],{"trials":818,"activeCount":11},[],{"intervention":810,"totalTrials":45,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":822,"activeCount":11},[],{"trials":824,"activeCount":11},[825],{"nctId":800,"briefTitle":801,"status":463,"phases":826,"primaryCompletion":803,"completion":804,"start":805,"enrollment":806,"conditions":827,"interventions":828},[37],[24,808],[793,810],{"trials":830,"activeCount":11},[],{"trials":832,"activeCount":11},[],{"trials":834,"activeCount":11},[],{"trials":836,"activeCount":11},[],{"intervention":838,"totalTrials":45,"cells":839},"Ag85B-ESAT6 fusion protein H1",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":841,"activeCount":11},[],{"trials":843,"activeCount":11},[844],{"nctId":845,"briefTitle":846,"status":463,"phases":847,"primaryCompletion":740,"completion":848,"start":849,"enrollment":9,"conditions":850,"interventions":852},"NCT00440544","A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)",[37],"2008-02","2007-01",[851],"Tuberculosis",[838,838,838,838,838,838],{"trials":854,"activeCount":11},[],{"trials":856,"activeCount":11},[],{"trials":858,"activeCount":11},[],{"trials":860,"activeCount":11},[],{"intervention":862,"totalTrials":45,"cells":863},"P2G12 Dose Cohort 1",{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":865,"activeCount":11},[],{"trials":867,"activeCount":11},[868],{"nctId":869,"briefTitle":870,"status":60,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":198,"conditions":875,"interventions":877},"NCT02923999","Study of Single IV Administration of P2G12",[37],"2020-08","2020-12","2019-08",[876],"HIV Infection",[862,878,879],"P2G12 Dose Cohort 2","P2G12 Dose Cohort 3",{"trials":881,"activeCount":11},[],{"trials":883,"activeCount":11},[],{"trials":885,"activeCount":11},[],{"trials":887,"activeCount":11},[],{"intervention":878,"totalTrials":45,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":891,"activeCount":11},[],{"trials":893,"activeCount":11},[894],{"nctId":869,"briefTitle":870,"status":60,"phases":895,"primaryCompletion":872,"completion":873,"start":874,"enrollment":198,"conditions":896,"interventions":897},[37],[876],[862,878,879],{"trials":899,"activeCount":11},[],{"trials":901,"activeCount":11},[],{"trials":903,"activeCount":11},[],{"trials":905,"activeCount":11},[],{"intervention":879,"totalTrials":45,"cells":907},{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":909,"activeCount":11},[],{"trials":911,"activeCount":11},[912],{"nctId":869,"briefTitle":870,"status":60,"phases":913,"primaryCompletion":872,"completion":873,"start":874,"enrollment":198,"conditions":914,"interventions":915},[37],[876],[862,878,879],{"trials":917,"activeCount":11},[],{"trials":919,"activeCount":11},[],{"trials":921,"activeCount":11},[],{"trials":923,"activeCount":11},[],{"intervention":925,"totalTrials":926,"cells":927},"Slow Sodium",2,{"EARLY_PHASE1":928,"PHASE1":930,"PHASE2":932,"PHASE3":934,"PHASE4":936,"NA":938},{"trials":929,"activeCount":11},[],{"trials":931,"activeCount":11},[],{"trials":933,"activeCount":11},[],{"trials":935,"activeCount":11},[],{"trials":937,"activeCount":11},[],{"trials":939,"activeCount":11},[940,949],{"nctId":941,"briefTitle":942,"status":88,"phases":943,"completion":944,"start":945,"enrollment":548,"conditions":946,"interventions":948},"NCT00141609","Haemodialysis Salt Reduction Study",[41],"2006-10","2004-04",[947,18],"Kidney Failure, Chronic",[925],{"nctId":950,"briefTitle":951,"status":88,"phases":952,"completion":944,"start":953,"enrollment":954,"conditions":955,"interventions":956},"NCT00141622","Sodium-Endothelial Function-CKD Study",[41],"2005-04",50,[947],[957],"Slow sodium",{"intervention":959,"totalTrials":45,"cells":960},"Boostrix-IPV",{"EARLY_PHASE1":961,"PHASE1":963,"PHASE2":965,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":962,"activeCount":11},[],{"trials":964,"activeCount":11},[],{"trials":966,"activeCount":11},[],{"trials":968,"activeCount":11},[],{"trials":970,"activeCount":11},[],{"trials":972,"activeCount":11},[973],{"nctId":974,"briefTitle":975,"status":60,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":954,"conditions":980,"interventions":983},"NCT03982732","Maternal Antibody in Milk After Vaccination",[],"2019-08-31","2019-10-31","2018-08-07",[26,96,981,982],"Pregnancy","Breastmilk",[959],{"intervention":985,"totalTrials":45,"cells":986},"Cardura XL 4 mg bd",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":997},{"trials":988,"activeCount":11},[],{"trials":990,"activeCount":11},[],{"trials":992,"activeCount":11},[],{"trials":994,"activeCount":11},[],{"trials":996,"activeCount":11},[],{"trials":998,"activeCount":11},[999],{"nctId":1000,"briefTitle":1001,"status":463,"phases":1002,"completion":944,"start":1003,"enrollment":1004,"conditions":1005,"interventions":1006},"NCT00141596","Extracellular Fluid in Resistant Hypertension",[41],"2003-07",32,[18],[985,1007,1008],"Amiloride 5 mg bd","Furosemide 40 mg bd",{"intervention":1007,"totalTrials":45,"cells":1010},{"EARLY_PHASE1":1011,"PHASE1":1013,"PHASE2":1015,"PHASE3":1017,"PHASE4":1019,"NA":1021},{"trials":1012,"activeCount":11},[],{"trials":1014,"activeCount":11},[],{"trials":1016,"activeCount":11},[],{"trials":1018,"activeCount":11},[],{"trials":1020,"activeCount":11},[],{"trials":1022,"activeCount":11},[1023],{"nctId":1000,"briefTitle":1001,"status":463,"phases":1024,"completion":944,"start":1003,"enrollment":1004,"conditions":1025,"interventions":1026},[41],[18],[985,1007,1008],{"intervention":1008,"totalTrials":45,"cells":1028},{"EARLY_PHASE1":1029,"PHASE1":1031,"PHASE2":1033,"PHASE3":1035,"PHASE4":1037,"NA":1039},{"trials":1030,"activeCount":11},[],{"trials":1032,"activeCount":11},[],{"trials":1034,"activeCount":11},[],{"trials":1036,"activeCount":11},[],{"trials":1038,"activeCount":11},[],{"trials":1040,"activeCount":11},[1041],{"nctId":1000,"briefTitle":1001,"status":463,"phases":1042,"completion":944,"start":1003,"enrollment":1004,"conditions":1043,"interventions":1044},[41],[18],[985,1007,1008],{"intervention":1046,"totalTrials":45,"cells":1047},"Fluid challenge with Compound Sodium Lactate",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1058},{"trials":1049,"activeCount":11},[],{"trials":1051,"activeCount":11},[],{"trials":1053,"activeCount":11},[],{"trials":1055,"activeCount":11},[],{"trials":1057,"activeCount":11},[],{"trials":1059,"activeCount":11},[1060],{"nctId":1061,"briefTitle":1062,"status":88,"phases":1063,"primaryCompletion":1064,"completion":1064,"start":466,"enrollment":1065,"conditions":1066,"interventions":1068},"NCT02569008","Minimal Volume for Fluid Challenge in Post-operative Patients",[41],"2015-02",80,[1067],"Post Cardiac Surgery",[1046],{"intervention":1070,"totalTrials":45,"cells":1071},"protein analysis",{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1078,"PHASE4":1080,"NA":1082},{"trials":1073,"activeCount":11},[],{"trials":1075,"activeCount":11},[],{"trials":1077,"activeCount":11},[],{"trials":1079,"activeCount":11},[],{"trials":1081,"activeCount":11},[],{"trials":1083,"activeCount":11},[1084],{"nctId":1085,"briefTitle":1086,"status":60,"phases":1087,"primaryCompletion":172,"start":804,"enrollment":1088,"conditions":1089,"interventions":1094},"NCT00972400","Fatigue in Breast Cancer Survivors",[],96,[1090,1091,1092,1093],"Breast Cancer","Cancer Survivor","Fatigue","Psychosocial Effects of Cancer and Its Treatment",[1070],{"intervention":1096,"totalTrials":45,"cells":1097},"Enalapril 20 mg bd",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1106,"NA":1108},{"trials":1099,"activeCount":11},[],{"trials":1101,"activeCount":11},[],{"trials":1103,"activeCount":11},[],{"trials":1105,"activeCount":11},[],{"trials":1107,"activeCount":11},[],{"trials":1109,"activeCount":11},[1110],{"nctId":1111,"briefTitle":1112,"status":463,"phases":1113,"completion":944,"start":945,"enrollment":1114,"conditions":1115,"interventions":1116},"NCT00141583","The Renin-Angiotensin System in Essential Hypertension",[41],11,[18],[1096,1117],"Candesartan 8 mg bd",{"intervention":1117,"totalTrials":45,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1121,"activeCount":11},[],{"trials":1123,"activeCount":11},[],{"trials":1125,"activeCount":11},[],{"trials":1127,"activeCount":11},[],{"trials":1129,"activeCount":11},[],{"trials":1131,"activeCount":11},[1132],{"nctId":1111,"briefTitle":1112,"status":463,"phases":1133,"completion":944,"start":945,"enrollment":1114,"conditions":1134,"interventions":1135},[41],[18],[1096,1117],{"intervention":1137,"totalTrials":45,"cells":1138},"Vaccination with a pertussis containing vaccine",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1140,"activeCount":11},[],{"trials":1142,"activeCount":11},[],{"trials":1144,"activeCount":11},[],{"trials":1146,"activeCount":11},[],{"trials":1148,"activeCount":11},[],{"trials":1150,"activeCount":11},[1151],{"nctId":1152,"briefTitle":1153,"status":88,"phases":1154,"primaryCompletion":1155,"completion":1156,"start":1157,"enrollment":1158,"conditions":1159,"interventions":1160},"NCT03284515","Vaccination In Pregnancy Gene Signature: VIP Signature Study",[],"2018-01-31","2018-03-21","2017-09-07",30,[28,96],[1137],{"intervention":1162,"totalTrials":45,"cells":1163},"Pre-school booster vaccine",{"EARLY_PHASE1":1164,"PHASE1":1166,"PHASE2":1168,"PHASE3":1170,"PHASE4":1172,"NA":1174},{"trials":1165,"activeCount":11},[],{"trials":1167,"activeCount":11},[],{"trials":1169,"activeCount":11},[],{"trials":1171,"activeCount":11},[],{"trials":1173,"activeCount":11},[],{"trials":1175,"activeCount":11},[1176],{"nctId":1177,"briefTitle":1178,"status":88,"phases":1179,"primaryCompletion":1180,"completion":1180,"start":1181,"enrollment":1182,"conditions":1183,"interventions":1186},"NCT03578120","Immunising Mums Against Pertussis 3",[],"2020-03-01","2018-04-24",64,[1184,1185,149],"Whooping Cough","Maternal Vaccine Exposure",[1162],{"intervention":1188,"totalTrials":45,"cells":1189},"Reconstituted High Density Lipoprotein",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1198,"NA":1200},{"trials":1191,"activeCount":11},[],{"trials":1193,"activeCount":11},[],{"trials":1195,"activeCount":11},[],{"trials":1197,"activeCount":11},[],{"trials":1199,"activeCount":11},[],{"trials":1201,"activeCount":11},[1202],{"nctId":1203,"briefTitle":1204,"status":88,"phases":1205,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":1209,"conditions":1210,"interventions":1211},"NCT00822302","Trial to Evaluate the Ability of a Single Infusion of High-Density Lipoprotein (HDL) to Modulate Markers of Cerebral Ischaemia",[41],"2008-12","2009-02","2006-02",40,[15],[1188,1212],"Saline",{"intervention":1212,"totalTrials":45,"cells":1214},{"EARLY_PHASE1":1215,"PHASE1":1217,"PHASE2":1219,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1216,"activeCount":11},[],{"trials":1218,"activeCount":11},[],{"trials":1220,"activeCount":11},[],{"trials":1222,"activeCount":11},[],{"trials":1224,"activeCount":11},[],{"trials":1226,"activeCount":11},[1227],{"nctId":1203,"briefTitle":1204,"status":88,"phases":1228,"primaryCompletion":1206,"completion":1207,"start":1208,"enrollment":1209,"conditions":1229,"interventions":1230},[41],[15],[1188,1212],{"intervention":1232,"totalTrials":45,"cells":1233},"Gut infection challenge with M bovis",{"EARLY_PHASE1":1234,"PHASE1":1236,"PHASE2":1238,"PHASE3":1240,"PHASE4":1242,"NA":1244},{"trials":1235,"activeCount":11},[],{"trials":1237,"activeCount":11},[],{"trials":1239,"activeCount":11},[],{"trials":1241,"activeCount":11},[],{"trials":1243,"activeCount":11},[],{"trials":1245,"activeCount":11},[1246],{"nctId":1247,"briefTitle":1248,"status":88,"phases":1249,"primaryCompletion":805,"completion":805,"start":742,"enrollment":16,"conditions":1250,"interventions":1252},"NCT01074775","Human Innate Immune Responses To Mycobacterial Aerodigestive Tract Infection",[41],[1251],"Bacterial Infections",[1232],{"intervention":1254,"totalTrials":45,"cells":1255},"Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads",{"EARLY_PHASE1":1256,"PHASE1":1258,"PHASE2":1260,"PHASE3":1262,"PHASE4":1264,"NA":1266},{"trials":1257,"activeCount":11},[],{"trials":1259,"activeCount":11},[],{"trials":1261,"activeCount":11},[],{"trials":1263,"activeCount":11},[],{"trials":1265,"activeCount":11},[],{"trials":1267,"activeCount":11},[1268],{"nctId":1269,"briefTitle":1270,"status":88,"phases":1271,"primaryCompletion":314,"completion":172,"start":1272,"enrollment":198,"conditions":1273,"interventions":1275},"NCT00949572","Measuring Responses to Sublingual Antigens",[41],"2009-09",[1274],"Sexually Transmitted Diseases, Viral",[1254,1254]]